Tonix Pharmaceuticals Holding Corp. (TNXP)

$0.14

Market is closed - opens 7 PM, 09 Oct 2024

Performance

  • $0.14
    $0.16
    $0.14
    downward going graph

    1.57%

    Downside

    Day's Volatility :15.41%

    Upside

    14.06%

    downward going graph
  • $0.12
    $22.14
    $0.14
    downward going graph

    15.71%

    Downside

    52 Weeks Volatility :99.47%

    Upside

    99.37%

    downward going graph

Returns

PeriodTonix Pharmaceuticals Holding Corp.Sector (Health Care)Index (Russel 2000)
3 Months
-76.65%
4.7%
0.0%
6 Months
-97.64%
5.9%
0.0%
1 Year
-99.23%
16.3%
0.0%
3 Years
-100.0%
19.6%
-20.8%

Highlights

Market Capitalization
19.7M
Book Value
$4.28
Earnings Per Share (EPS)
-139.08
PEG Ratio
0.0
Wall Street Target Price
21.0
Profit Margin
0.0%
Operating Margin TTM
-831.48%
Return On Assets TTM
-51.72%
Return On Equity TTM
-163.24%
Revenue TTM
12.5M
Revenue Per Share TTM
6.35
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-90.8M
Diluted Eps TTM
-139.08
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-14.38
EPS Estimate Next Year
-30.91
EPS Estimate Current Quarter
-3.27
EPS Estimate Next Quarter
-3.11

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Tonix Pharmaceuticals Holding Corp.(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 14900.0%

Current $0.14
Target $21.00

Technicals Summary

Sell

Neutral

Buy

Tonix Pharmaceuticals Holding Corp. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp.
-14.84%
-97.64%
-99.23%
-100.0%
-100.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-12.19%
6.5%
20.85%
84.03%
245.65%
Novo Nordisk A/s
Novo Nordisk A/s
-11.15%
-6.13%
27.31%
138.21%
354.53%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
5.38%
73.95%
61.12%
32.59%
252.19%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.58%
13.46%
29.21%
155.56%
172.0%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp.
NA
NA
0.0
-14.38
-1.63
-0.52
NA
4.28
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.37
26.37
1.36
45.03
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
38.76
38.76
1.75
3.39
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.49
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.54
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp.
Buy
$20.1M
-100.0%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$109.8B
245.65%
26.37
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$512.4B
354.53%
38.76
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$34.2B
252.19%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$115.8B
172.0%
32.84
-4.74%

Insights on Tonix Pharmaceuticals Holding Corp.

  • Decreasing Revenue

    Revenue is down for the last 5 quarters, 33.90M → 2.20M (in $), with an average decrease of 34.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -14.93M → -78.77M (in $), with an average decrease of 427.3% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 61.1% return, outperforming this stock by 160.3%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 33.1% return, outperforming this stock by 133.1%

Institutional Holdings

  • Prudential Financial Inc

    0.09%

  • Alyeska Investment Group, L.P.

    0.06%

  • Vanguard Group Inc

    0.02%

  • HRT FINANCIAL LLC

    0.02%

  • Geode Capital Management, LLC

    0.02%

  • JANE STREET GROUP, LLC

    0.01%

Company Information

tonix is developing innovative pharmaceutical products to address major public health challenges. in addition to tonmya for ptsd, tonix is developing tnx-601 (tianeptine oxalate), a clinical candidate at pre-ind (investigational new drug) application stage, designed as a daytime treatment for ptsd and tnx-801, a live synthetic version of horsepox virus, at the pre-ind application stage, to be developed as a potential smallpox-preventing vaccine. further information about tonix can be found at www.tonixpharma.com.

Organization
Tonix Pharmaceuticals Holding Corp.
Employees
103
CEO
Dr. Seth Lederman M.D.
Industry
Health Technology

Discover More

FAQs